Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2 Trial of 5-fluorouracil, Leucovorin, Irinotecan in Combination With Temozolomide (FLIRT) and Bevacizumab for the First-line Treatment of Patients With MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.

NCT04689347 is registered in ClinicalTrials.gov with Fondazione IRCCS Istituto Nazionale dei Tumori, Milano as lead sponsor.

NCT NCT04689347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04689347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2 Trial of 5-fluorouracil, Leucovorin, Irinotecan in Combination With Temozolomide (FLIRT) and Bevacizumab for the First-line Treatment of Patients With MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.
Lead sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 1, 2021
Completion date
January 31, 2027
Enrollment
27 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer